New Haven, Connecticut (NYSE: BHVN) November 13, 2017 – Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, or the “Company”) and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced the appointment of Scott Phillips as the Company’s Senior Vice President (SVP) of Finance. Mr. Phillips will focus on further advancing Biohaven’s infrastructure to support the Company’s accounting, external reporting and finance capabilities.
Jim Engelhart, Chief Financial Officer of Biohaven, commented, “Scott brings extensive accounting, reporting, internal control, and other financial expertise to our finance leadership team. This is a critical expertise for Biohaven to have internally as we continue to adhere to the multiple and expanding reporting and compliance obligations of being a public company.”
Scott Phillips, SVP Finance
Scott Phillips joins Biohaven with nearly 20 years of accounting and finance experience in both the pharmaceutical industry and public accounting practice. Most recently, he was employed by Alexion Pharmaceuticals (“Alexion”), Inc, a Nasdaq-listed company, where he served as Chief Accounting Officer and then SVP of Global Business Finance. Scott was responsible for expanding the accounting organization and internal control structure from a pre-commercial business to a global accounting organization supporting over 50 countries. In these roles, Scott’s responsibilities included overseeing Alexion’s accounting, SEC reporting, Sarbanes-Oxley Section 404 compliance, tax, shared services and financial planning and analysis functions. Prior to Alexion, Scott served as Senior Audit Manager at PricewaterhouseCoopers. Scott is a CPA and holds a B.S. and a Masters degree in Accounting from the University of North Carolina at Chapel Hill.
“I am thrilled to join the dynamic Biohaven team during this exciting period of growth. I look forward to contributing my experience in building strong finance organizations as we further establish our processes and controls as a newly public company,” said Mr. Phillips.
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Currently, Biohaven’s lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulation platforms. The company’s common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN. More information about Biohaven is available at www.biohavenpharma.com.
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410